In the high-stakes world of biopharmaceutical manufacturing, the term "technology transfer" is often treated as a clinical, administrative milestone—a box to be checked on the road from laboratory bench to patient bedside. However, beneath the veneer of meticulous documentation and regulatory filings, a quiet crisis is unfolding. As the industry increasingly relies on Contract Development and Manufacturing Organizations (CDMOs) to scale production, an essential, intangible asset is being left behind: tacit knowledge.
Tacit knowledge—the "know-how," the intuitive grasp of process nuances, and the lessons learned from failed experiments—is rarely captured in standard operating procedures (SOPs) or batch records. As biopharma companies aggressively outsource and manufacturing teams face the dual pressures of workforce turnover and retirement-age departures, this critical expertise is vanishing. The implications for the industry are profound, particularly as it shifts toward complex cell and gene therapies where "operator technique" can be the difference between a life-saving dose and a failed batch.
The Anatomy of the Knowledge Gap
Technology transfer is the foundational process of moving documented knowledge from one unit to another—from R&D to pilot plants, or from in-house labs to external CDMO partners. While over 86% of biopharma companies now outsource at least some portion of their manufacturing, the mechanism of transfer is fundamentally flawed.
Ryan Chen, director of Product Marketing at ValGenesis, observes that tech transfer is a recurring challenge across the entire product lifecycle. "Technology transfer occurs repeatedly across the lifecycle: from CMC development to first GMP clinical supply, and further down to commercial scale, between manufacturing sites and even post-approval when capacity, network or process/method changes are required," Chen explains.
The problem lies in the distinction between "explicit" knowledge—what is written in a protocol—and "tacit" knowledge, which is stored in the minds of scientists and technicians. When a scientist translates a research-scale process into a commercial-scale manufacturing environment, the "why" and "how" of certain decisions often remain unwritten. If a process requires a subtle manual adjustment to account for slight temperature fluctuations or shear stress, and that adjustment is not codified, it effectively ceases to exist once the original researcher moves on.
Chronology of a Disappearing Workforce
The urgency of this issue is compounded by a demographic and economic "perfect storm" currently reshaping the biopharma labor market.
- The Demographic Shift: The United States is currently witnessing approximately 11,000 baby boomers reaching retirement age every single day. This cohort represents the most experienced generation of process engineers and scientists, many of whom hold decades of institutional memory regarding complex manufacturing challenges.
- The 2025 Retrenchment: The industry has faced significant headwinds, with biopharma layoffs rising by 16% in 2025. Manufacturing and CDMO functions, often viewed as overhead in lean-management models, have been disproportionately affected.
- The Loss of Institutional Memory: When a manufacturing site undergoes layoffs or a CDMO experiences high staff turnover, the "tribal knowledge" that keeps production consistent is decimated. Unlike raw data, this expertise cannot be easily recovered from a database.
This erosion of knowledge is not merely a staffing inconvenience; it is a financial and operational liability. Merck, for instance, famously reported $125 million in value attributable to structured knowledge management over a ten-year period, highlighting that when knowledge is retained, efficiency and bottom-line performance soar. Conversely, when it is lost, companies incur massive costs in troubleshooting, deviation investigations, and lost batches.
Supporting Data: Why Documentation Isn’t Enough
The pharmaceutical industry is inherently document-centric, governed by strict regulatory frameworks. However, both the PDA (Parenteral Drug Association) and the ISPE (International Society for Pharmaceutical Engineering) have signaled that the industry’s reliance on paper-based compliance is failing to capture the reality of modern manufacturing.
The ISPE’s Good Practice Guide on Knowledge Management in the Pharmaceutical Industry explicitly labels tacit knowledge as "arguably underappreciated." Despite this, there is no regulatory framework that mandates specific methods for capturing the intuitive expertise of a senior scientist.
The disconnect is most visible in the transition from academia to industry. "Academic to industry packages are often associated with immature processes and undocumented tacit knowledge," notes Chen. In an academic setting, the goal is discovery, not scalability. Scientists are encouraged to be creative and flexible, often improvising when equipment fails or results are unexpected. In a GMP (Good Manufacturing Practice) environment, that same improvisation is viewed as a "deviation." If the tacit reasons for those academic improvisations are not formally translated into robust, scalable systems, the transfer is doomed to encounter friction.
The High Stakes of Advanced Modalities
If the loss of knowledge is a challenge for small-molecule drugs, it is an existential threat to cell and gene therapies (CGTs). Unlike traditional pharmaceuticals, which are chemically synthesized and relatively stable, advanced modalities involve living cells—highly sensitive, inherently variable, and biologically complex.
The Human Factor in CAR-T
In CAR-T cell therapy manufacturing, the process is as much an art as it is a science. Steps like cell isolation, expansion, and harvesting are often manual, requiring high levels of operator skill.
- Operator Technique: In a manual CAR-T process, the way an operator maneuvers a pipette or interprets the output of a flow cytometer can directly influence yield.
- Aseptic Processing: Because living cells cannot be terminally sterilized (as they would be killed in the process), every step is a potential point of contamination. The "tacit" comfort level an operator has with aseptic technique is a critical quality attribute.
- Biological Variability: No two batches of patient cells are identical. An experienced operator "knows" how to adjust based on the visual or analytical feedback of the cells in real-time. If that experience is not captured, the process becomes brittle.
"Global manufacturing networks add jurisdictional GMP differences, supply chain variability and cross-site comparability expectations," says Chen. When a company tries to transfer a CAR-T process to a CDMO across the globe, they aren’t just transferring a protocol; they are attempting to transfer a physical habit. Without a strategy to map and train these nuances, the "comparability" required by regulators becomes impossible to prove.
Implications for Future Governance
The industry stands at a crossroads. Relying on traditional tech transfer models—where a PDF of an SOP is sent to a CDMO and considered "transferred"—is no longer sufficient. To survive the current landscape, the industry must pivot toward a more proactive, knowledge-centric governance model.
1. Designing for Transfer Early
Companies must stop treating tech transfer as a "late-stage operational task." Instead, it should be an integrated part of early-stage CMC (Chemistry, Manufacturing, and Controls) development. By documenting the "failed attempts" and the "why" behind process parameters, companies can build a knowledge base that survives the transfer.
2. Institutionalizing Knowledge Management
Organizations need to adopt tools that go beyond simple document management. This includes video-based training, virtual reality simulations for complex operator techniques, and structured "debrief" sessions after every batch to capture the subtle observations of the production team.
3. Selecting for Modality Expertise
Founders and biotech executives must shift their criteria for selecting CDMO partners. It is no longer enough to look at physical capacity or cost. Companies must assess whether a partner has the governance and culture to absorb and sustain the specific, tacit knowledge required for their unique therapeutic modality.
4. A Call for Regulatory Evolution
While the PDA’s Technical Report No. 65 provides a roadmap, the industry would benefit from clearer regulatory expectations regarding knowledge retention. If regulators begin to demand evidence of "knowledge transfer" as part of the comparability package, companies will be forced to elevate this from an HR concern to a core quality and compliance mandate.
Conclusion
The loss of tacit knowledge is the silent thief of biopharmaceutical innovation. As the industry scales, and as the workforce turns over, companies that treat knowledge as a static asset will inevitably fall behind. In the era of cell and gene therapy, the "human element"—the intuition, the technique, and the memory of the experienced practitioner—is a critical component of the product itself.
Bridging the gap between what is written on a page and what is understood in the mind of the scientist is the next great frontier for the biopharmaceutical industry. Those who master the art of transferring expertise, not just documentation, will be the ones who successfully scale the next generation of life-saving therapies.
About the Author
